Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion
This Lancet publication addresses basilar artery occlusion, the most severe presentation of large-vessel ischemic stroke, with new randomized and observational evidence supporting intravenous tenecteplase therapy within an extended 24-hour treatment window.
Summary
Basilar artery occlusion is a devastating condition with dismal prognosis and constitutes the most severe presentation of acute ischaemic stroke due to large-vessel occlusion.1 Randomised evidence on the safety and efficacy of intravenous thrombolysis in this stroke subtype is scarce, especially outside the conventional 0–4·5 h window.1,2 Tenecteplase is a third-generation tissue plasminogen activator with higher fibrin specificity and longer half-life than alteplase.3 Accruing randomised and observational evidence supports the superiority of tenecteplase over alteplase in patients who have had an acute ischaemic stroke, particularly those with large-vessel occlusion, in improving 3-month functional outcome assessed by the modified Rankin scale (mRS) score.
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
